/PRNewswire/ -- Johnson & Johnson announced today new clinical and real-world evidence data will be featured in 18 abstracts at this year's ASCO GU Symposium...

Related Keywords

Japan , San Francisco , California , United States , Japanese , Luca Dezzani , Obrian Kenney , Kiran Patel , Laboratory Abnormalities , Exchange Commission , York Heart Association , Janssen Research Development , Astex Pharmaceuticals , Janssen Pharmaceuticals , Clinical Development , None Of Janssen Research Development , Early Development , Data Monitoring Committee , European Medicines Agency , Janssen Biotech Inc , Johnson , Janssen Scientific Affairs , Vice President , Solid Tumors , Johnson Innovative , Medical Affairs , Bacillus Calmette Gu , Breakthrough Therapy Designation , Acute Myeloid Leukemia , Fluid Retention , Cardiovascular Adverse Reactions , Torsades De Pointes , New York Heart Association , Independent Data Monitoring Committee , Reversible Encephalopathy Syndrome , Posterior Reversible Encephalopathy Syndrome , Fetal Toxicity , Prescribing Information , Ischemic Cardiovascular Events , Cutaneous Adverse Reactions , All Grades , Soft Tissue Mineralization , Embryo Fetal Toxicity , Innovative Medicine , Janssen Research , Janssen Biotech , Private Securities Litigation Reform Act , Annual Report , Note Regarding Forward Looking , Quarterly Reports , Participants With Advanced Solid Tumors , Fibroblast Growth Factor Receptor , Accessed May , Johnson Amp ,